Chembio Diagnostics, Inc. (CEMI) Announces Membership In Russell Global Index

Jun. 28, 2013 11:03 AM ETCEMI
Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Contributor Since 2008

QualityStocks (www.qualitystocks.net) assists publicly traded companies by getting their story out to the investment community while helping investors discover emerging companies with plenty of growth potential. Our name, QualityStocks, emphasizes our commitment to connect subscribers with companies that have huge potential to succeed in the short and long-term future. QualityStocks provides investor relations services to publicly traded companies in exchange for compensation. The content we provide via Seeking Alpha may be part of our efforts to widen a client’s exposure. To read our full disclaimer, visit http://disclaimer.qualitystocks.net.

Point-of-care diagnostics test leader Chembio Diagnostics announced it will soon join the Russell Global Index. According to a preliminary list of additions posted on June 21 at russell.com/indexes, the listing will happen on June 28, when Russell Investments reconstitutes its comprehensive set of U.S. and global equity indexes.

Russell Global Index membership remains in place for one year and means automatic inclusion in the appropriate large-cap, small-cap and all-cap indexes, as well as the applicable style, sector, and country indexes. Membership for Russell's equity indexes is determined chiefly by objective market-capitalization rankings and style attributes. Chembio's stock will be included in Russell's Micro-Cap Index.

Chembio continues to build momentum with both sales and product development and is currently in a very strong position. The company's membership in the Russell Global Index is occurring at a time when Chembio has experienced four consecutive years of profitability and revenue growth. The company now has three FDA-approved rapid HIV tests, including its oral fluid HIV test which is pending CLIA waiver and strong international sales. Chembio is additionally developing a robust POC product pipeline based on the company's patented DPP technology.

"We are very pleased to join the list of successful companies comprising the Russell Global Index and look forward to the enhanced visibility of our membership," said Chembio Chairman and CEO Lawrence A. Siebert.

Chembio Diagnostics is engaged in developing, manufacturing, licensing, and marketing proprietary rapid diagnostic tests in the burgeoning $10 billion point-of-care testing market. The company is headquartered in Medford, N.Y., and has approximately 170 employees. Chembio is licensed by the FDA and the USDA and is also certified for the global market under the International Standards Organization (ISO) directive 13.485.

For more information, visit chembio.com

Please see disclaimer on the QualityStocks website: disclaimer.qualitystocks.net

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.